Dramamine is not a drug of abuse, and it is not a target on any standard employment drug panel. The active ingredient in original Dramamine, dimenhydrinate, is not an analyte that any 5 panel, 10 panel, or DOT regulated screen is built to detect. The question employees and employers actually mean to ask is narrower: can taking Dramamine cause a false positive on a screen that is looking for something else. The honest answer is that it can, in a small number of documented cases, because of how the body processes dimenhydrinate rather than because Dramamine itself is a controlled substance.
What is actually in Dramamine
Dimenhydrinate is a combination compound. Once it is absorbed, the body splits it into two pieces: 8 chloratheophylline and diphenhydramine, the same antihistamine sold on its own as Benadryl. Diphenhydramine is the piece that does the sedating and antinausea work, and it is also the piece that shows up in urine. The over the counter label for original Dramamine tablets lists dimenhydrinate 50 mg as the sole active ingredient and identifies the product as an antiemetic for motion sickness, as published on the DailyMed label for Dramamine Original Formula.
That distinction matters for drug testing, because almost everything published about dimenhydrinate and screening interference is really a study of its diphenhydramine metabolite, not of dimenhydrinate as a separate molecule.
Screening immunoassay versus confirmation testing
Workplace and clinical drug tests almost always run in two stages. The first stage is an immunoassay, a fast chemical test that uses antibodies tuned to recognize the general shape of a drug class. Immunoassays are cheap and fast, but the antibodies are not perfectly selective. A molecule that resembles the target closely enough can bind the antibody and trigger a presumptive positive even though the actual drug of interest is not present. That is a cross reactivity event, not a true positive.
The second stage, run only on specimens that screen positive, is a confirmation test using gas chromatography mass spectrometry (GC/MS) or liquid chromatography tandem mass spectrometry (LC/MS or LC/MS/MS). These methods separate and identify molecules by their exact mass and structure. A compound that falsely triggers an immunoassay will not produce the confirmatory pattern of the drug the screen was looking for, so confirmation testing is what clears a cross reactivity false positive. Federal workplace drug testing programs run on this same two step screen and confirm model, and the Substance Abuse and Mental Health Services Administration maintains the certified laboratory list and the Medical Review Officer manual and resources that support it, described on its drug testing resources page.
What the published research actually says about diphenhydramine
There is a real, published body of literature on diphenhydramine interfering with specific immunoassays. It is older literature, mostly from the 1980s and 1990s clinical chemistry journals, and it is narrow rather than broad. Three drug classes have documented reports.
Phencyclidine (PCP) screens
A clinical chemistry research report titled "Effects of diphenhydramine on immunoassays of phencyclidine in urine" is indexed on PubMed and documents that diphenhydramine, at concentrations reachable with ordinary over the counter dosing, can produce a positive result on certain PCP immunoassays. This is the best documented of the three cross reactivity patterns tied to diphenhydramine.
Methadone screens
Two separate clinical chemistry journal letters, indexed on PubMed with the National Library of Medicine subject headings "Diphenhydramine" and "Methadone" together with "False Positive Reactions," describe diphenhydramine producing a positive result on the EMIT drugs of abuse urine assay used for methadone. Both are cataloged as a 1984 report and a 1985 follow up report with the same finding. The reports predate most of today's laboratory antibody formulations, so the degree of cross reactivity on current generation methadone immunoassays is not something a published, recent study has re measured. That is a gap in the evidence, not a confirmed non issue.
Tricyclic antidepressant (TCA) screens
This is the pattern with the clearest clinical documentation. A toxicology case report, indexed on PubMed, describes an infant with a dimenhydrinate overdose whose initial serum immunoassay read positive for tricyclic antidepressants. A repeat analysis by GC/MS a few hours later identified diphenhydramine specifically, with no tricyclic antidepressant present, and the false positive resolved once confirmation testing ran. A separate laboratory letter indexed on PubMed reports the same type of diphenhydramine interference on a tricyclic antidepressant immunoassay in a different patient. A third paper on adapting a TCA immunoassay for urine use states plainly that "the TCA assay cross reacts with phenothiazines and antihistamines," naming diphenhydramine among the cross reacting compounds.
Outside of these three documented patterns, there is no credible published cross reactivity evidence tying dimenhydrinate or diphenhydramine to amphetamine, cocaine, cannabinoid (THC), benzodiazepine, or opiate immunoassays. If a screen flags positive for one of those classes after Dramamine use, the more likely explanations are a different medication, a supplement, or an actual analyte in the specimen, and the confirmation test is what sorts that out.
Meclizine: a different molecule, different notes
The "less drowsy" Dramamine formulation does not contain dimenhydrinate at all. It uses meclizine hydrochloride, a chemically distinct antihistamine that does not metabolize into diphenhydramine. The DailyMed label for Dramamine Less Drowsy lists meclizine hydrochloride 25 mg as the sole active ingredient. Meclizine has its own, separate set of reported screening notes that are not the same as diphenhydramine's, and an employee should not assume the two products carry identical risk on a panel. Anyone comparing the two should treat them as different active ingredients with different literature, not as interchangeable motion sickness pills.
OTC motion sickness and sleep aids: what each can affect on a screen
| Product | Active ingredient | Documented screening note |
|---|---|---|
| Dramamine (original) | Dimenhydrinate (metabolizes to diphenhydramine) | Published reports of cross reactivity on some PCP, methadone, and TCA immunoassays |
| Dramamine Less Drowsy, Bonine | Meclizine | Different compound than diphenhydramine; separate, limited literature |
| Benadryl, store brand diphenhydramine | Diphenhydramine | Same cross reactivity pattern described above, since it is the same molecule |
| Unisom SleepTabs | Doxylamine | Different antihistamine; evaluated separately in its own literature, not identical to diphenhydramine |
| Unisom SleepGels, ZzzQuil, most NyQuil formulas | Diphenhydramine | Same documented pattern as diphenhydramine above |
| Claritin, Zyrtec | Loratadine or cetirizine | No credible published cross reactivity evidence against standard drug testing immunoassays |
A practical note for the cold and allergy aisle: any product containing diphenhydramine, whether it is sold as Benadryl, as a sleep aid, or combined into a nighttime cold formula, carries the same documented interference pattern, because the active molecule in the body is identical. For a closer look at that specific pairing, see this site's piece on diphenhydramine and false positive screens and the companion piece on meclizine and panel screens.
What to do before and after a test
Dimenhydrinate is sold without a prescription, so there is usually no prescription record to hand a lab. The practical steps are the same ones that apply to any over the counter medication that might affect a screen.
- Tell the collector or the clinic intake form what over the counter medications were taken recently, including the brand name and the active ingredient if it is known.
- If a result comes back as a non negative screen, the specimen should go to confirmation testing by GC/MS or LC/MS before anyone treats it as a true positive.
- In a reviewed program, a Medical Review Officer is the person who contacts the donor, asks about medications, and decides whether a confirmed result has a legitimate explanation. The SAMHSA Medical Review Officer manual and resources describe that review role in detail.
- Keep the original packaging or a photo of the label if a question comes up later. A label showing "dimenhydrinate" or "meclizine hydrochloride" as the active ingredient is a fast way to clear up which product was actually taken.
None of this is a way to beat a test, and it should not be read as one. Dimenhydrinate is not a controlled substance and does not need to be hidden from an employer or a lab. The point of documenting it is the opposite: it gives the Medical Review Officer or the reviewing clinician an accurate, verifiable reason for a presumptive result so the confirmation process can resolve it correctly.
Where this fits for employers running a drug free workplace program
Employers who see an unexpected non negative screening result on an immunoassay should rely on the confirmation step rather than acting on the screen alone, and should route any medication explanation through the Medical Review Officer process rather than asking a supervisor to make that call. Programs that use dip cards or cups for initial screening and send non negative results to a certified laboratory for GC/MS or LC/MS confirmation are following the same model SAMHSA describes for federal testing programs. American Screening Corporation supplies both the initial screening devices and the lab confirmation pathway that programs like this depend on; its current drug test cup collection is built around that screen and confirm workflow.
Frequently asked questions
Does Dramamine show up on a standard 5 panel or 10 panel drug test?
No. Dimenhydrinate is not one of the analytes a standard panel is designed to detect, and it is not a controlled substance.
Can Dramamine cause a false positive for PCP?
There is a published clinical chemistry report describing diphenhydramine, the metabolite of dimenhydrinate, causing a positive result on certain PCP immunoassays. A confirmation test by GC/MS or LC/MS resolves whether PCP is actually present.
Can Dramamine cause a false positive for methadone?
Older published clinical chemistry letters describe diphenhydramine interfering with a methadone immunoassay used at the time. Current generation assays have not been separately re tested in a published study, so this should be treated as a documented possibility rather than a settled, current rate.
Does Dramamine affect a tricyclic antidepressant (TCA) screen?
Yes, this is the most clearly documented pattern. Published case reports and laboratory letters describe diphenhydramine producing a false positive tricyclic antidepressant result that cleared on confirmation testing.
Is meclizine (Dramamine Less Drowsy) different from Dramamine on a drug test?
Yes. Meclizine is a different antihistamine that does not metabolize into diphenhydramine, and it has its own separate, more limited screening literature. It should not be assumed to carry the same notes as original Dramamine.
What should someone do if Dramamine triggers a non negative screen?
Tell the collector or the Medical Review Officer which over the counter product and active ingredient was used, and let the specimen go through GC/MS or LC/MS confirmation before treating the screen as a final result.
This article is general information about drug test screening and confirmation science. It is not medical advice, legal advice, or a diagnosis, and it is not guidance for avoiding or beating a drug test. Anyone with questions about a specific result should talk to the testing program's Medical Review Officer or their own physician.
